Anti-human Claudin 18.2 Monoclonal Antibody (zolbetuximab)

產(chǎn)品型號(hào)：S0B1436

更新時(shí)間：2025-10-11

廠商性質(zhì)：生產(chǎn)廠家

訪問(wèn)量：137

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

重組兔單抗：解鎖生命科學(xué)研究新大門的神奇鑰匙

CDx 抗體 | 新興靶點(diǎn)B7-H3/H4，助力ADC藥物研發(fā)

如何利用非天然氨基酸開(kāi)發(fā)高選擇性去泛素化酶探針？

sFlt-1：妊娠風(fēng)險(xiǎn)的精準(zhǔn)預(yù)測(cè)因子

產(chǎn)品介紹

Claudin 18.2 monoclonal antibodies are a promising class of therapeutic agents targeting the Claudin 18.2 protein, a tight junction protein that is highly expressed in various cancers, including gastric, pancreatic, and ovarian cancers. In normal tissues, Claudin 18.2 is predominantly expressed in differentiated gastric mucosal cells, but its upregulation in tumor cells makes it an attractive target for cancer therapy. These monoclonal antibodies, such as Zolbetuximab, work by binding specifically to the extracellular domain of Claudin 18.2, inducing antibody-dependent cellular cytotoxicity （ADCC） and complement-dependent cytotoxicity （CDC） to kill cancer cells.

上一個(gè)：S0B2367PMAFA Recombinant Rabbit mAb,PBS Only (SDT-2040-6)